Reports on the conditional approval granted by the National Institutes of Health Recombinant DNA Advisory Committee to the study on the proposed gene therapy for lung cancer during the March 3-4, 1994 meeting. Reason given for the conditional approval; Call for more data to be presented; Background on the protocol proposed by study researcher Jack Roth; Other stumbling blocks to the study.